Crosstalk between endothelial cell and thrombus in chronic thromboembolic pulmonary hypertension: Perspective

Histology and Histopathology

Volumn 28, Issue 2, 2013, Pages 185-193

  Sakao, Seiichiro ^a   Tatsumi, Koichiro ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

CTEPH; Endothelial cell; Thrombus

Indexed keywords

APOPTOSIS; CELL COMMUNICATION; CHRONIC DISEASE; DISEASE COURSE; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; LUNG EMBOLISM; MICROVASCULATURE; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PULMONARY HYPERTENSION; REVIEW; THROMBOSIS; VASCULAR ENDOTHELIUM;

APOPTOSIS; CELL COMMUNICATION; CHRONIC DISEASE; DISEASE PROGRESSION; ENDOTHELIUM, VASCULAR; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; HYPERTENSION, PULMONARY; MICROVESSELS; PULMONARY EMBOLISM; THROMBOSIS;

EID: 84873801468     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. Ameshima S., Golpon H., Cool C.D., Chan D., Vandivier R.W., Gardai S.J., Wick M., Nemenoff R.A., Geraci M.W. and Voelkel N.F. (2003). Peroxisome proliferatoractivated receptor gamma (PPARgamma) expression is decreased in pulmonary hypertension and affects endothelial cell growth. Circ. Res. 92, 1162-1169.
2. Andree H.A., Stuart M.C., Hermens W.T., Reutelingsperger C.P., Hemker H.C., Frederik P.M. and Willems G.M. (1992). Clustering of lipid-bound annexin V may explain its anticoagulant effect. J. Biol. Chem. 267, 17907-17912.
3. Archer S.L., Gomberg-Maitland M., Maitland M.L., Rich S., Garcia J.G. and Weir E.K. (2008). Mitochondrial metabolism, redox signaling, and fusion: a mitochondria-ROS-HIF-1alpha-Kv1.5 O2-sensing pathway at the intersection of pulmonary hypertension and cancer. Am. J. Physiol. Heart. Circ. Physiol. 294, 570-578.
4. Arciniegas E., Ponce L., Hartt Y., Graterol A. and Carlini R.G. (2000). Intimal thickening involves transdifferentiation of embryonic endothelial cells. Anat. Rec. 258, 47-57.
5. Arciniegas E., Frid M.G., Douglas I.S. and Stenmark K.R. (2007). Perspectives on endothelial-to-mesenchymal transition: potential contribution to vascular remodeling in chronic pulmonary hypertension. Am. J. Physiol. Lung. Cell. Mol. Physiol. 293, L1-8.
6. Azarian R., Wartski M., Collignon M.A., Parent F., Herve P., Sors H. and Simonneau G. (1997). Lung perfusion scans and hemodynamics in acute and chronic pulmonary embolism. J. Nucl. Med. 38, 980-983.
7. Bauer M., Wilkens H., Langer F., Schneider S.O., Lausberg H. and Schafers H.J. (2002). Selective upregulation of endothelin B receptor gene expression in severe pulmonary hypertension. Circulation 105, 1034-1036.
8. Bonderman D., Turecek P.L., Jakowitsch J., Weltermann A., Adlbrecht C., Schneider B., Kneussl M., Rubin L.J., Kyrle P.A., Klepetko W., Maurer G. and Lang I.M. (2003). High prevalence of elevated clotting factor VIII in chronic thromboembolic pulmonary hypertension. Thromb. Haemost. 90, 372-376.
9. Condliffe R., Kiely D.G., Gibbs J.S, Corris P.A., Peacock A.J., Jenkins D.P., Hodgkins D., Goldsmith K., Hughes R.J., Sheares K., Tsui S.S., Armstrong I.J., Torpy C., Crackett R., Carlin C.M., Das C., Coghlan J.G. and Pepke-Zaba J. (2008). Improved outcomes in medically and surgically treated chronic thromboembolic pulmonary hypertension. Am. J. Respir. Crit. Care. Med. 177, 1122-1127.
10. Cool C.D., Wood K. and Voelkel N.F. (2004). Transdifferentiation of endothelial cells in primary pulmonary hypertension. Am. J. Resp. Crit. Care. Med. 167: A844.
11. Collen D. and Lijnen H.R. (2005). Thrombolytic agents. Thromb. Haemost. 93, 627-630.
12. Dartevelle P., Fadel E., Mussot S., Chapelier A., Herve P., de Perrot M., Cerrina J., Ladurie F.L., Lehouerou D., Humbert M., Sitbon O. and Simonneau G. (2004). Chronic thromboembolic pulmonary hypertension. Eur. Respir. J. 23, 637-648.
13. Egermayer P., Town G.I. and Peacock A.J. (1999). The role of serotonin in the pathophysiology of acute and chronic pulmonary hypertension. Thorax 54, 161-168.
14. Eisenberg P.R., Lucore C., Kaufman L., Sobel B.E., Jaffe A.S. and Rich S. (1990). Fibrinopeptide A levels indicative of pulmonary vascular thrombosis in patients with primary pulmonary hypertension. Circulation 82, 841-847.
15. Ellis C.A., Tiruppathi C., Sandoval R., Niles W.D. and Malik A.B. (1999). Time course of recovery of endothelial cell surface thrombin receptor (PAR-1) expression. Am. J. Physiol. Cell. Physiol. 276, C38-C45.
16. Firth A.L., Yau J., White A., Chiles P.G., Marsh J.J., Morris T.A. and Yuan J.X. (2009). Chronic exposure to fibrin and fibrinogen differentially regulates intracellular Ca2+ in human pulmonary arterial smooth muscle and endothelial cells. Am. J. Physiol. Lung Cell. Mol. Physiol. 296, L979-986.
17. Firth A.L., Yao W., Ogawa A., Madani M.M., Lin G.Y. and Yuan J.X. (2010). Multipotent mesenchymal progenitor cells are present in endaretectomized tissues from patients with chronic thromboembolic pulmonary hypertension. Am. J. Physiol. Cell. Physiol. 298, C1217-C1225.
18. Funakoshi T., Heimark R.L., Hendrickson L.E., McMullen B.A. and Fujikawa K. (1987). Human placental anticoagulant protein: isolation and characterization. Biochemistry 26, 5572-5578.
19. Hoeper M.M., Mayer E., Simonneau G. and Rubin L. (2006). Chronic thromboembolic pulmonary hypertension. Circulation 113, 2011-2020.
20. Humbert M., Morrell N.W., Archer S.L., Stenmark K.R., MacLean M.R., Lang I.M., Christman B.W., Weir E.K., Eickelberg O., Voelkel N.F. and Rabinovitch M. (2004). Cellular and molecular pathobiology of pulmonary arterial hypertension. J. Am. Coll. Cardiol. 43, 13S-24S.
21. Jamieson S.W., Kapelanski D.P., Sakakibara N., Manecke G.R., Thistlethwaite P.A., Kerr K.M., Channick R.N., Fedullo P.F. and Auger W.R. (2003). Pulmonary endarterectomy: experience and lessons learned in 1,500 cases. Ann. Thorac. Surg. 76, 1457-1462.
22. Kimura H., Okada O., Tanabe N., Tanaka Y., Terai M., Takiguchi Y., Masuda M., Nakajima N., Hiroshima K., Inadera H., Matsushima K. and Kuriyama T. (2001). Plasma monocyte chemoattractant protein- 1 and pulmonary vascular resistance in chronic thromboembolic pulmonary hypertension. Am. J. Respir. Crit. Care. Med. 164, 319-324.
23. Klepetko W., Mayer E., Sandoval J., Trulock E.P., Vachiery J.L., Dartevelle P., Pepke-Zaba J., Jamieson S.W., Lang I. and Corris P. (2004). Interventional and surgical modalities of treatment for pulmonary arterial hypertension. J. Am. Coll. Cardiol. 43 (suppl S), 73S-80S.
24. Lang I.M., Marsh J.J., Olman M.A., Moser K.M., Loskutoff D.J. and Schleef R.R. (1994a). Expression of type 1 plasminogen activator inhibitor in chronic pulmonary thromboemboli. Circulation 89, 2715-2721.
25. Lang I.M., Marsh J.J., Olman M.A., Moser K.M. and Schleef R.R. (1994b). Parallel analysis of tissue-type plasminogen activator and type-1 plasminogen activator inhibitor in plasma and endothelial cells derived from patients with chronic pulmonary thromboemboli. Circulation 90, 706-712.
26. Majesky M.W. and Schwartz S.M. (1997). An origin for smooth muscle cells from endothelium? Circ. Res. 80, 601-603.
27. Maruoka M., Sakao S., Kantake M., Tanabe N., Kasahara Y., Kurosu K., Takiguchi Y., Masuda M., Yoshino I., Voelkel N.F. and Tatsumi K. (2012). Characterization of myofibroblasts in chronic thromboembolic pulmonary hypertension. Int. J. Cardiol. 159, 119-127.
28. Masri F.A., Xu W., Comhair S.A., Asosingh K., Koo M., Vasanji A., Drazba J., Anand-Apte B. and Erzurum S.C. (2007). Hyperproliferative apoptosis-resistant endothelial cells in idiopathic pulmonary arterial hypertension. Am. J. Physiol. Lung. Cell. Mol. Physiol. 293, L548-L554.
29. Matsuda M. and Sugo T. (2002). Structure and function of human fibrinogen inferred from dysfibrinogens. Int. J. Hematol. 76, 352-360.
30. Moncada S., Palmer R.M. and Higgs E.A. (1991). Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol. Rev. 43, 109-142.
31. Morris T.A., Marsh J.J., Chiles P.G., Auger W.R., Fedullo P.F. and Woods V.L. Jr (2006). Fibrin derived from patients with chronic thromboembolic pulmonary hypertension is resistant to lysis. Am. J. Respir. Crit. Care. Med. 173, 1270-1275.
32. Morris T.A., Marsh J.J., Chiles P.G., Kim N.H., Noskovack K.J., Magana M.M., Gruppo R.A. and Woods V.L. Jr (2007). Abnormally sialylated fibrinogen gamma-chains in a patient with chronic thromboembolic pulmonary hypertension. Thromb. Res. 119, 257-259.
33. Moser K.M. and Bloor C.M. (1993). Pulmonary vascular lesions occurring in patients with chronic major vessel thromboembolic pulmonary hypertension. Chest 103, 685-692.
34. Peacock A., Simonneau G. and Rubin L. (2006). Controversies, uncertainties and future research on the treatment of chronic thromboembolic pulmonary hypertension. Proc. Am. Thorac. Soc. 3, 608-614.
35. Pi X., Yan C. and Berk B.C. (2004). Big mitogen-activated protein kinase (BMK1)/ERK5 protects endothelial cells from apoptosis. Circ. Res. 94, 362-9.
36. Piazza G. and Goldhaber S.Z. (2011). Chronic thromboembolic pulmonary hypertension. N. Engl. J. Med. 364, 351-360.
37. Reesink H.J., Lutter R., Kloek J.J., Jansen H.M. and Bresser P. (2004). Hemodynamic correlates of endothelin-1 in chronic thromboembolic pulmonary hypertension. Eur. Respir. J. 24, 110s.
38. Reesink H.J., Meijer R.C., Lutter R., Boomsma F., Jansen H.M., Kloek J.J. and Bresser P. (2006). Hemodynamic and clinical correlates of endothelin-1 in chronic thromboembolic pulmonary hypertension. Circ. J. 70, 1058-1063.
39. Robin E.D., Cross C.E., Kroetz F., Totten R.S. and Bron K. (1966). Pulmonary hypertension and unilateral pleural constriction with speculation on pulmonary vasoconstrictive substance. Arch. Intern. Med. 118, 391-400.
40. Sakamaki F., Kyotani S., Nagaya N., Sato N., Oya H. and Nakanishi N. (2003). Increase in thrombomodulin concentrations after pulmonary thromboendarterectomy in chronic thromboembolic pulmonary hypertension. Chest 124, 1305-1311.
41. Sakao S., Taraseviciene-Stewart L., Cool C.D., Tada Y., Kasahara Y., Kurosu K., Tanabe N., Takiguchi Y., Tatsumi K., Kuriyama T. and Voelkel N.F. (2007). VEGF-R blockade causes endothelial cell apoptosis, expansion of surviving CD34+ precursor cells and transdifferentiation to smooth muscle-like and neuronal-like cells. FASEB J. 21, 3640-3652.
42. Sakao S., Taraseviciene-Stewart L., Lee J.D., Wood K., Cool C.D. and Voelkel N.F. (2005). Initial apoptosis is followed by increased proliferation of apoptosis-resistant endothelial cells. FASEB J. 19, 1178-1180.
43. Sakao S., Tatsumi K. and Voelkel N.F. (2009). Endothelial cells and pulmonary arterial hypertension: apoptosis, proliferation, interaction and transdifferentiation. Respir. Res. 10, 95.
44. Sakao S., Tatsumi K. and Voelkel N.F. (2010). Reversible or irreversible remodeling in pulmonary arterial hypertension. Am. J. Respir. Cell. Mol. Biol. 43, 629-634.
45. Sakao S., Hao H., Tanabe N., Kasahara Y., Kurosu K. and Tatsumi K. (2011). Endothelial-like cells in chronic thromboembolic pulmonary hypertension: crosstalk with myofibroblast-like cells. Respir. Res. 12,109.
46. Seyfarth H.J., Halank M., Wilkens H., Schäfers H.J., Ewert R., Riedel M., Schuster E., Pankau H., Hammerschmidt S. and Wirtz H. (2010). Standard PAH therapy improves long term survival in CTEPH patients. Clin. Res. Cardiol. 99, 553-556.
47. Shure D. (1996). Thrombendartectomy: some unanswered questions. Ann. Thorac. Surg. 62, 1253-1254.
48. Skoro-Sajer N., Hack N., Sadushi-Koliçi R., Bonderman D., Jakowitsch J., Klepetko W., Hoda M.A., Kneussl M.P, Fedullo P. and Lang I.M. (2009). Pulmonary vascular reactivity and prognosis in patients with chronic thromboembolic pulmonary hypertension: a pilot study. Circulation 119, 298-305.
49. Sofia M., Faraone S., Alifano M., Micco A., Albisinni R., Maniscalco M. and Di Minno G. (1997). Endothelin abnormalities in patients with pulmonary embolism. Chest 111, 544-549.
50. Suntharalingam J., Goldsmith K., van Marion V., Long L., Treacy C.M., Dudbridge F., Toshner M.R., Pepke-Zaba J., Eikenboom J.C. and Morrell N.W. (2008). Fibrinogen AThr312Ala polymorphism is associated with chronic thromboembolic pulmonary hypertension. Eur. Respir. J. 31, 736-741.
51. Tait J.F., Sakata M., McMullen B.A., Miao C.H., Funakoshi T., Hendrickson L.E. and Fujikawa K. (1988). Placental anticoagulant proteins: isolation and comparative characterization four members of the lipocortin family. Biochemistry 27, 6268-6276.
52. Tanabe N., Sugiura T., Jujo T., Sakao S., Kasahara Y., Kato H., Masuda M. and Tatsumi K. (2012). Subpleural perfusion as a predictor for a poor surgical outcome in chronic thromboembolic pulmonary hypertension. Chest 14, 929-934.
53. Taraseviciene-Stewart L., Kasahara Y., Alger L., Hirth P., Mc Mahon G., Waltenberger J., Voelkel N.F. and Tuder R.M. (2001). Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension. FASEB J. 15, 427-438.
54. Torbicki A., Perrier A., Konstantinides S., Agnelli G., Galiè N., Pruszczyk P., Bengel F., Brady A.J., Ferreira D., Janssens U., Klepetko W., Mayer E., Remy-Jardin M. and Bassand J.P. (2008). ESC Committee for Practice Guidelines (CPG). Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur. Heart J. 29, 2276-2315.
55. Ulrich S., Fischler M., Speich R., Popov V. and Maggiorini M. (2006). Chronic thromboembolic and pulmonary arterial hypertension share acute vasoreactivity properties. Chest 130, 841-846.
56. Voges D., Berendes R., Burger A., Demange P., Baumeister W. and Huber R. (1994). Three-dimensional structure of membrane-bound annexin V. A correlative electron microscopy-X-ray crystallography study. J. Mol. Biol. 238, 199-213.
57. Welsh C.H., Hassell K.L., Badesch D.B., Kressin D.C. and Marlar R.A. (1996). Coagulation and fibrinolytic profiles in patients with severe pulmonary hypertension. Chest 110, 710-717.
58. Wolf M., Boyer-Neumann C., Parent F., Eschwege V., Jaillet H., Meyer D. and Simonneau G. (2000). Thrombotic risk factors in pulmonary hypertension. Eur. Respir. J. 15, 395-399.
59. Yao W., Firth A.L., Sacks R.S., Ogawa A., Auger W.R., Fedullo P.F., Madani M.M., Lin G.Y., Sakakibara N., Thistlethwaite P.A., Jamieson S.W., Rubin L.J. and Yuan J.X. (2009). Identification of putative endothelial progenitor cells (CD34+CD133+Flk-1+) in endarterectomized tissue of patients with chronic thromboembolic pulmonary hypertension. Am. J. Physiol. Lung. Cell. Mol. Physiol. 296, L870-878.
60. Yi E.S., Kim H., Ahn H., Strother J., Morris T., Masliah E., Hansen L.A., Park K. and Friedman P.J. (2000). Distribution of obstructive intimal lesions and their cellular phenotypes in chronic pulmonary hypertension: a morphometric and immunohistochemical study. Am. J. Respir. Crit. Care. Med. 162, 1577-1586.